271 related articles for article (PubMed ID: 24078498)
1. Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
Imran M; Najmi AK; Tabrez S
Urol J; 2013 Sep; 10(3):935-40. PubMed ID: 24078498
[TBL] [Abstract][Full Text] [Related]
2. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
3. Mirabegron: A new option in treating overactive bladder.
Turpen HC; Zimmern PE
JAAPA; 2015 Nov; 28(11):16, 18. PubMed ID: 26501573
[TBL] [Abstract][Full Text] [Related]
4. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
5. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
7. Possible Involvement of Muscarinic Receptor Blockade in Mirabegron Therapy for Patients with Overactive Bladder.
Yamada S; Chimoto J; Shiho M; Okura T; Morikawa K; Wakuda H; Shinozuka K
J Pharmacol Exp Ther; 2021 May; 377(2):201-206. PubMed ID: 33658313
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
10. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men.
Otsuki H; Kosaka T; Nakamura K; Mishima J; Kuwahara Y; Tsukamoto T
Int Urol Nephrol; 2013 Feb; 45(1):53-60. PubMed ID: 23212147
[TBL] [Abstract][Full Text] [Related]
11. What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Caremel R; Loutochin O; Corcos J
Int Urogynecol J; 2014 Feb; 25(2):165-70. PubMed ID: 23922008
[TBL] [Abstract][Full Text] [Related]
12. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
15. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review.
Yeowell G; Smith P; Nazir J; Hakimi Z; Siddiqui E; Fatoye F
BMJ Open; 2018 Nov; 8(11):e021889. PubMed ID: 30467131
[TBL] [Abstract][Full Text] [Related]
16. β3-receptor agonists for overactive bladder--new frontier or more of the same?
Andersson KE
Curr Urol Rep; 2013 Oct; 14(5):435-41. PubMed ID: 23677692
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
19. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]